Last update 12 Dec 2024

RO7790121

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
RO7790121
Target
VEGI
Mechanism
VEGI modulators(Tumor necrosis factor superfamily member 15 modulators)
Therapeutic Areas
Immune System DiseasesDigestive System Disorders
Active Indication
Ulcerative colitis, active severeUlcerative colitis, active moderateCrohn Disease
Inactive Indication-
Originator Organization
F. Hoffmann-La Roche Ltd.
Active Organization
F. Hoffmann-La Roche Ltd.Hoffmann-La Roche, Inc.
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Related

5
Clinical Trials associated with RO7790121
NCT06588855 / RecruitingPhase 3
A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Patients With Moderately to Severely Active Ulcerative Colitis
NCT06589986 / RecruitingPhase 3
A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 in Patients With Moderately to Severely Active Ulcerative Colitis
NCT05910528 / Active, not recruitingPhase 2
A Phase 2, Multicenter, Double-blind, Two-arm Study of Subcutaneous RO7790121 for the Treatment of Subjects With Moderate to Severe Active Crohn's Disease
100 Clinical Results associated with RO7790121
Login to view more data
100 Translational Medicine associated with RO7790121
Login to view more data
100 Patents (Medical) associated with RO7790121
Login to view more data
100 Deals associated with RO7790121
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Ulcerative colitis, active severePhase 3
US
F. Hoffmann-La Roche Ltd.
07 Nov 2024
Ulcerative colitis, active severePhase 3
CN
F. Hoffmann-La Roche Ltd.
07 Nov 2024
Ulcerative colitis, active moderatePhase 3
BE
Hoffmann-La Roche, Inc.
17 Sep 2024
Ulcerative colitis, active moderatePhase 3
PT
Hoffmann-La Roche, Inc.
17 Sep 2024
Crohn DiseasePhase 2
US
-24 Jul 2023
Crohn DiseasePhase 2
BE
-24 Jul 2023
Crohn DiseasePhase 2
BG
-24 Jul 2023
Crohn DiseasePhase 2
CA
-24 Jul 2023
Crohn DiseasePhase 2
FR
-24 Jul 2023
Crohn DiseasePhase 2
DE
-24 Jul 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free